Tubulin inhibitor SP-1-39 with anti-pd-l1 for enhanced cancer immunotherapy
SP-1-39, a novel tubulin inhibitor, enhances PD-L1 expression on tumor cells, increasing susceptibility to anti-PD-L1 therapy. This combination aims to improve T cell-mediated cancer treatment efficacy by overcoming resistance in metastatic cancers.
Overview
SP-1-39 is a novel tubulin inhibitor designed to enhance the effectiveness of cancer immunotherapy by increasing PD-L1 expression on tumor cells. This upregulation primes the tumor microenvironment for immune checkpoint blockade, potentially overcoming common resistance mechanisms in PD-L1-targeted therapies. The combination of SP-1-39 with anti-PD-L1 aims to synergistically enhance anti-tumor immune responses, thereby improving therapeutic efficacy in metastatic cancer.
Technical specifications
Key features:
- PD-L1 Upregulation: SP-1-39 induces significant PD-L1 expression on tumor cells, enhancing their visibility to the immune system.
- Combination Treatment: When used with anti-PD-L1, SP-1-39 enhances T cell-mediated killing of cancer cells.
- Research Methods: Validation includes flow cytometry, Western blotting, and qPCR to measure PD-L1 expression, and co-culture models to assess T cell cytotoxicity.
- In Vivo Studies: Utilizes mouse models to track tumor burden, metastatic spread, apoptosis, and immune cell infiltration.
Technology readiness level
This technology is currently at TRL 4, indicating that it has been validated in laboratory environments using both in vitro and in vivo studies to demonstrate its potential efficacy in enhancing cancer immunotherapy.
About University of Tennessee Health Science Center
The University of Tennessee Health Science Center is a public academic health sciences institution headquartered in Memphis, serving the state through comprehensive colleges in the health professions and a statewide network of clinical education sites. Industry collaborates through integrated partnerships with teaching hospitals across Memphis, Chattanooga, Knoxville, and Nashville, providing access to diverse patient populations, real-world data, and clinician investigators for sponsored studies and translation. Shared core facilities, biobanking capabilities, and translational research spaces—along with simulation and surgical training environments—support contract research, prototyping and validation, and multicenter trials coordination. Research is supported by competitive federal funding led by the NIH, with additional awards from other national agencies. A dedicated technology transfer office manages IP, licensing, sponsored-research agreements, and startup support to accelerate commercialization.
Inquire about this partnering listing
Industry applications
delivered to your inbox.